Severe @entity130 has been shown to result in @entity5886 . @entity5886 can cause cardiac, hematologic, immunologic, and @entity4094 . This study compares serum phosphate levels and outcomes in @entity1 who were administered a continuous, preemptive phosphate repletion protocol vs those who only received phosphate supplementation after they developed @entity5886 . Records of @entity1 with greater than 19% TBSA burn admitted to the intensive care unit from 2006 to 2010 were reviewed. @entity1 were divided into two groups: historical controls who received responsive repletion when serum phosphate levels were less than 2.5 mg/dl (2006-2008) and the experimental group that received 30 mmol intravenous every 6 hours starting at approximately 24 hours after injury as long as serum phosphate levels were less than 4 mg/dl (2008-2010). @entity1 with @entity740 or @entity810 were excluded. Data collected included age, weight, burn size, age, all serum phosphate levels, and total amount of phosphate administered. Differences in groups were compared with Mann-Whitney U test and Fisher's exact test. A total of 30 @entity1 were included in the study, 20 in the responsive repletion group and 10 in the continuous repletion group. No significant difference was detected in age, sex, burn size, or full thickness burn size between groups. The continuous group had a statistically lower percentage of hypophosphatemic lab values compared with the responsive group, 13    14% vs 45    21% (P < .0001). No difference was found in percent of observations reflecting @entity2265 (median of 2% in each group, P = .7). Four @entity1 in the continuous group suffered @entity299 compared with 16 in the responsive group (P = .04). Continuous, pre-emptive repletion of phosphate prevents @entity5886 after @entity130 when compared with responsive repletion in historical controls. The protocol resulted in less @entity5886 without increasing the risk of @entity2265 . This study also suggests that continuous repletion may result in fewer complications, but this needs to be confirmed in larger, prospective studies.

Prevention of @entity5886 after XXXX with a protocol for continuous, preemptive repletion.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular dysfunction'] @entity740 :: ('MESH:D051436', 'Disease') :: ['chronic kidney disease'] @entity5886 :: ('MESH:D017674', 'Disease') :: ['Hypophosphatemia', 'hypophosphatemia'] @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute kidney injury'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac and/or infectious complications'] @entity130 :: ('MESH:D014947', 'Disease') :: ['burn injury', 'severe burn injury']
@entity130 :: (MESH:D014947,Disease) :: ['burn injury']
